BCTK announced that it has completed the Series A round of financing, jointly invested by Qingshan Qiuse Investment, Kunshan High-tech Venture Capital and others. Including the A1 round, the cumulative financing amount of the company reached nearly 60 million yuan. WinX Capital serves as the sole financial advisor and long-term capital advisor.
Upon the completion of the fresh funding, BCTK will further accelerated the research and development and industrialization of the combination of innovative devices and medicine-loaded innovative reagent for cancer surgery.
BCTK is located in the biomedical industrial park of Kunshan High-tech Zone, Jiangsu Province, and is the first batch of small nucleic acid biomedical innovation alliance enterprises. The company is committed to the development of regenerative medicine and new materials that can replace and repair human tissues and organs, and provides a series of innovative reagent combined with medicine and devices.
At present, the core technology of innovative products of BCTK has gained the national invention patent and has strong technical barriers. The company has established a gene therapy drug technology platform in cooperation with international partners.